190 related articles for article (PubMed ID: 17598018)
1. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time.
Love JE; Ferrell C; Chandler WL
Thromb Haemost; 2007 Jul; 98(1):234-42. PubMed ID: 17598018
[TBL] [Abstract][Full Text] [Related]
2. Alternative monitoring of argatroban using plasma-diluted thrombin time.
Wanat MA; Hart SR; Putney D; Liebl MG; Chandler W
Ann Pharmacother; 2013 Apr; 47(4):e18. PubMed ID: 23482736
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Seidel H; Kolde HJ
Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
5. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
[TBL] [Abstract][Full Text] [Related]
6. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
7. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
8. Monitoring Direct Thrombin Inhibitors With Calibrated Diluted Thrombin Time vs Activated Partial Thromboplastin Time in Pediatric Patients.
Hasan RA; Pak J; Kirk CJ; Friedland-Little JM; Chandler WL
Am J Clin Pathol; 2023 Jan; 159(1):60-68. PubMed ID: 36351044
[TBL] [Abstract][Full Text] [Related]
9. Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant.
Salmela B; Joutsi-Korhonen L; Saarela E; Lassila R
Thromb Res; 2010 Jun; 125(6):538-44. PubMed ID: 20181379
[TBL] [Abstract][Full Text] [Related]
10. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
11. Methods for the monitoring of direct thrombin inhibitors.
Hafner G; Roser M; Nauck M
Semin Thromb Hemost; 2002 Oct; 28(5):425-30. PubMed ID: 12420237
[TBL] [Abstract][Full Text] [Related]
12. Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Weiss C; Harenberg J
Blood Coagul Fibrinolysis; 2004 Oct; 15(7):605-11. PubMed ID: 15389129
[TBL] [Abstract][Full Text] [Related]
13. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
14. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
Van Cott EM; Roberts AJ; Dager WE
Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
[TBL] [Abstract][Full Text] [Related]
15. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
Curvers J; van de Kerkhof D; Stroobants AK; van den Dool EJ; Scharnhorst V
Am J Clin Pathol; 2012 Oct; 138(4):551-8. PubMed ID: 23010710
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.
Beyer JT; Lind SE; Fisher S; Trujillo TC; Wempe MF; Kiser TH
J Thromb Thrombolysis; 2020 Feb; 49(2):259-267. PubMed ID: 31559512
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model.
McGlasson DL; Harroff HH; Sutton J; Dick E; Elston DM
Clin Lab Sci; 2007; 20(2):99-105. PubMed ID: 17557708
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of anticoagulant effects of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Harenberg J
Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
[TBL] [Abstract][Full Text] [Related]
19. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
[TBL] [Abstract][Full Text] [Related]
20. Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety.
Kamali F; Wood P; Ward A
Ann Hematol; 2009 Feb; 88(2):141-9. PubMed ID: 18716776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
